Fentanyl Test Evidence
Has Caused a False Positive
Ciprofloxacin
Source Fitch et al., Clin Chem 2023
What It Found
- Clinical samples with unconfirmed fentanyl screens contained ciprofloxacin.
- Spiked urine turned positive above 40 micrograms/mL, a level observed in five of six false-positive specimens evaluated for ciprofloxacin.
Keep in Mind
- This evidence concerns the ARK II reagent.
- A negative experiment on a different drug-test panel does not rule this out.
Test Studied
- ARK Fentanyl II, 1 ng/mL cutoff
Dextromethorphan
Source LZI Fentanyl Enzyme Immunoassay, FDA 510(k) decision summary K181159, 2018
What It Found
- The earlier reagent produced a positive with 40,000 ng/mL dextromethorphan in drug-free urine.
Test Studied
- Lin-Zhi LZI fentanyl EIA (K181159)
Source Uljon et al., J Appl Lab Med 2024
What It Found
- In a later Lin-Zhi II study, two people with known dextromethorphan exposure had unconfirmed low-positive screens.
Keep in Mind
- The clinical study considered dextromethorphan a likely explanation.
- One exposure was an overdose.
Test Studied
- A later Lin-Zhi Fentanyl II study
Both sources LZI Fentanyl Enzyme Immunoassay, FDA 510(k) decision summary K181159, 2018 Uljon et al., J Appl Lab Med 2024
Keep in Mind
- Neither study estimates risk at labeled cough doses.
Haloperidol
Source Wang et al., Drug Alcohol Depend 2024
What It Found
- Haloperidol was among three drugs implicated in clinical samples and verified by spiking urine.
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- The FDA decision summary also documents a positive result with added haloperidol.
Both sources Wang et al., Drug Alcohol Depend 2024 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Keep in Mind
- Evidence concerns the specific SEFRIA method.
- A personal chance of a false positive was not measured.
Test Studied
- Immunalysis SEFRIA
Methamphetamine
Source Abbott et al., J Anal Toxicol 2022
What It Found
- A forensic laboratory traced a series of unexpected screens to urine methamphetamine above 40 micrograms/mL on the Neogen assay.
Test Studied
- Neogen urine fentanyl ELISA at 1 ng/mL
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- The SEFRIA submission also reports reactivity at 70 micrograms/mL.
Test Studied
- SEFRIA analytical challenge
Both sources Abbott et al., J Anal Toxicol 2022 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Keep in Mind
- The finding concerns high urine concentrations.
- Testing drug powders with a fentanyl strip is a separate application.
Ofloxacin
Source Fitch et al., Clin Chem 2023
What It Found
- Desmethyl-ofloxacin produced a positive signal at a concentration found in clinical specimens.
- Ofloxacin itself produced a partial response and the N-oxide metabolite did not react.
Keep in Mind
- These findings concern urine concentrations associated with systemic exposure.
- Eye and ear preparations were not assessed.
Test Studied
- ARK Fentanyl II, 1 ng/mL cutoff
Paliperidone
2 sources Wang et al., J Anal Toxicol 2014 Li et al., Clin Chem 2020
What It Found
- Paliperidone is 9-hydroxyrisperidone and reacted in laboratory testing.
Source False-positive fentanyl urine screening during treatment with paliperidone: a case report, 2026
What It Found
- A patient receiving paliperidone screened positive, with neither fentanyl nor its metabolites detected on follow-up LC-MS/MS.
Test Studied
- A separate clinical urine case
All 3 sources Wang et al., J Anal Toxicol 2014 Li et al., Clin Chem 2020 False-positive fentanyl urine screening during treatment with paliperidone: a case report, 2026
Keep in Mind
- The direct paliperidone case and studies of the risperidone metabolite do not establish a frequency across assays or formulations.
Risperidone
Source Wang et al., J Anal Toxicol 2014
What It Found
- Five of seven DRI false positives contained risperidone and its active metabolite.
- Reagent testing confirmed reactivity.
Test Studied
- Thermo DRI
Source Shroitman et al., Psychiatry Res 2021
What It Found
- Additional reports include three patients taking long-acting injectable risperidone.
3 sources Wang et al., J Anal Toxicol 2014 Li et al., Clin Chem 2020 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Keep in Mind
- The reaction depends on the kit and the concentration of parent drug and metabolites.
All 5 sources Wang et al., J Anal Toxicol 2014 Li et al., Clin Chem 2020 Shroitman et al., Psychiatry Res 2021 Di Trana et al., Clin Chem Lab Med 2026 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Keep in Mind
- A prescription alone cannot explain an individual result.
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Test Studied
- Immunalysis SEFRIA
3 sources Li et al., Clin Chem 2020 Shroitman et al., Psychiatry Res 2021 Di Trana et al., Clin Chem Lab Med 2026
Test Studied
- Selected rapid urine assays
Trazodone
Source Wang et al., Drug Alcohol Depend 2024
What It Found
- Trazodone was identified in the hospital's investigation of unconfirmed fentanyl screens.
- Spiking experiments reproduced interference.
Keep in Mind
- The study identified three major interferents together.
- Its percentages do not measure an individual trazodone user's risk.
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- The original submission also found reactivity with high concentrations of the metabolite mCPP.
Both sources Wang et al., Drug Alcohol Depend 2024 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Test Studied
- Immunalysis SEFRIA, 1 ng/mL manufacturer cutoff
Amitriptyline
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with amitriptyline at 75 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Benzylpiperazine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with benzylpiperazine at 50 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Chlorpromazine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with chlorpromazine at 75 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Clomipramine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with clomipramine at 45 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Cyclobenzaprine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with cyclobenzaprine at 100 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Desipramine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with desipramine at 100 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Diphenhydramine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with diphenhydramine at 100 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Doxepin
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with doxepin at 100 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Fenfluramine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with fenfluramine at 60 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Fluoxetine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with fluoxetine at 60 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Imipramine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with imipramine at 100 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Nortriptyline
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with nortriptyline at 100 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Pentazocine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with pentazocine at 75 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Phencyclidine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with phencyclidine at 100 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Pipamperone
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Urine spiked with pipamperone at 1.5 micrograms/mL met the fentanyl screen cutoff.
Keep in Mind
- Evidence comes from a reagent challenge.
- The study did not measure how often users reach this concentration or have an unconfirmed result.
Test Studied
- Immunalysis SEFRIA fentanyl, 1 ng/mL cutoff (FDA K161216)
Depends on the Brand of Test
Labetalol
Source Wang et al., Drug Alcohol Depend 2024
What It Found
- A hospital investigation found labetalol among the major interferents and reproduced interference by spiking.
Source Wanar et al., J Addict Med 2022
What It Found
- Three pregnant or recently pregnant patients also had presumptive fentanyl positives while taking it.
Keep in Mind
- Review labor analgesia as a separate possible source of true fentanyl.
Test Studied
- Separate perinatal urine case series
Source Hightop Fentanyl/Norfentanyl Urine Rapid Test Panel and home-use panel, FDA 510(k)…, 2024
Keep in Mind
- Hightop’s fentanyl line did not turn positive with labetalol at 100,000 ng/mL in its validation.
2 sources Wang et al., Drug Alcohol Depend 2024 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Test Studied
- Immunalysis SEFRIA
Loperamide
Both sources Geno et al., J Appl Lab Med 2022 Walsh et al., J Appl Lab Med 2025
What It Found
- At high concentrations, loperamide and its N-desmethyl metabolite triggered the first three assays.
Keep in Mind
- The studies do not show an ordinary antidiarrheal dose commonly causes this.
Test Studied
- Thermo DRI, Immunalysis HEIA and SEFRIA
Source Walsh et al., J Appl Lab Med 2025
What It Found
- The other three were negative under the follow-up study conditions.
Test Studied
- Comparative Abbott iCassette, ARK Fentanyl II and LZI II
Source Geno et al., J Appl Lab Med 2022
What It Found
- One patient specimen had enough loperamide-related material to explain the initial result.
Keep in Mind
- In the 2022 series, four of five samples containing loperamide or its metabolite also contained fentanyl.
Alfentanil
Source Hightop Fentanyl/Norfentanyl Urine Rapid Test Panel and home-use panel, FDA 510(k)…, 2024
What It Found
- The related anesthetic alfentanil produced a positive at 10,000 ng/mL in the device's spiking study.
Keep in Mind
- This laboratory concentration and test-specific result do not establish an incidence after surgical anesthesia.
Test Studied
- Hightop rapid urine panel, fentanyl line at 1 ng/mL
Source Wolf et al., Clin Biochem 2025
What It Found
- None of the four reagents detected added Alfentanil in the study’s series tested at 1, 10 and 100 ng/mL.
Keep in Mind
- This addresses the parent drug over the tested concentration range.
- Results need not extend to other reagents or metabolites.
Test Studied
- ARK Fentanyl II, Immunalysis Fentanyl Urine HEIA, Immunalysis SEFRIA, and Lin-Zhi Fentanyl II
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed less than 1% relative response to Alfentanil.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
Sufentanil
Source Hightop Fentanyl/Norfentanyl Urine Rapid Test Panel and home-use panel, FDA 510(k)…, 2024
What It Found
- Sufentanil, an opioid anesthetic related to fentanyl, produced a positive at 1,000 ng/mL in the device's spiking study.
Keep in Mind
- The parent-drug challenge did not establish how often the given concentration is reached after clinical use.
- The assay challenge did not establish how often the concentration is reached after clinical use.
Test Studied
- Hightop rapid urine panel, fentanyl line at 1 ng/mL
Source Williams et al., Clin Biochem 2023
What It Found
- Neither reagent detected norsufentanil, a metabolite of sufentanil, in the studied series up to 100 ng/mL.
Test Studied
- ARK Fentanyl II and Immunalysis SEFRIA
Source Wolf et al., Clin Biochem 2025
What It Found
- The four reagents did not detect the metabolite norsufentanil in the 1–100 ng/mL challenge series.
Test Studied
- ARK Fentanyl II, Immunalysis Fentanyl Urine HEIA, Immunalysis SEFRIA, and Lin-Zhi Fentanyl II
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed less than 1% relative response to Sufentanil.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
2 sources Williams et al., Clin Biochem 2023 Wolf et al., Clin Biochem 2025
Keep in Mind
- The negative challenges apply only to norsufentanil, a distinct metabolite.
A Related Drug the Test Picks Up
Butyrylfentanyl
Source Cole et al., Pediatrics 2015
What It Found
- A patient's urine screened positive for fentanyl during a reported butyrfentanyl overdose.
Keep in Mind
- This single case does not provide a reagent-specific threshold or prove performance on other fentanyl tests.
Test Studied
- Hospital urine fentanyl screen in a published overdose case
3 methylthienylfentanyl
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed 100% relative response to 3 methylthienylfentanyl.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
Acetylfentanyl
2 sources Wang et al., J Anal Toxicol 2014 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- Acetylfentanyl is a related synthetic opioid that can produce a positive fentanyl screen even when fentanyl itself is absent.
Keep in Mind
- This is an analogue exposure, distinct from interference by an unrelated prescribed medicine.
- The confirmation panel must include the relevant analogue to identify it.
What It Found
- The study team's 2015 validation abstract reports 50–59% reactivity for acetylfentanyl in urine spiked at 5, 10 and 25 ng/mL.
2 sources Tiscione and Wegner, J Anal Toxicol 2017 Wegner and Tiscione, American Academy of Forensic Sciences Annual Scientific Meeting, abstract K14 2015
Keep in Mind
- The exact urine percentages come from the conference report.
- They should not be assigned to all six compounds named in the final paper.
Test Studied
- Neogen fentanyl RTU ELISA in fortified human urine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
Test Studied
- Immunalysis SEFRIA
Carfentanil
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed 85% relative response to Carfentanil.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
Methylacetylfentanyl isomers
Source Barajas et al., J Appl Lab Med 2025
What It Found
- Ortho-, meta- and para-methylacetylfentanyl cross-reacted with the urine immunoassay in a proficiency challenge and shared signals with fentanyl in one mass spectrometry method.
Keep in Mind
- These are fentanyl analogues rather than routine medicines.
- The laboratory developed additional chemical markers to distinguish the isomers from fentanyl.
Test Studied
- ARK Fentanyl II and a specific LC-MS/MS fentanyl method
para-Fluorofentanyl
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed 100% relative response to para-Fluorofentanyl.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
Thienylfentanyl
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed 100% relative response to Thienylfentanyl.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
The Test Is Made to Find It
Fentanyl
2 sources Li et al., Clin Chem 2020 Stolbach et al., J Med Toxicol 2022
What It Found
- Medically administered fentanyl can give a genuine fentanyl result.
Tests Studied
- Fentanyl-specific urine immunoassay
- LC-MS/MS identifies parent drug or norfentanyl
Source Stolbach et al., J Med Toxicol 2022
What It Found
- The laboratory can compare the detected analytes with the medication and anesthesia record.
Keep in Mind
- A urine result alone does not specify the source, route, impairment or intent.
Source Siegel et al., Am J Obstet Gynecol 2023
What It Found
- Fentanyl in a labor epidural has produced true positives in maternal and neonatal urine.
Source Makowski et al., Ann Clin Lab Sci 1995
What It Found
- The assay detected fentanyl in urine from surgical patients receiving the drug.
- Its antibody responded less to norfentanyl than to fentanyl.
Keep in Mind
- The tested ELISA predates the current commercial platforms.
Test Studied
- Historical fentanyl-specific urine ELISA
Source Williams et al., Clin Biochem 2023
What It Found
- Norfentanyl showed approximately 7% relative reactivity with ARK II and 0.005% with the SEFRIA method studied.
Keep in Mind
- The metabolite is genuine.
- Different assays vary in their ability to detect it.
Test Studied
- ARK Fentanyl II and Immunalysis SEFRIA
Source Lam et al., J Appl Lab Med 2024
What It Found
- Two specimens from patients prescribed fentanyl were ARK-positive and FEN2-negative.
- The authors found that different parent-drug and norfentanyl cutoffs affected detection.
Keep in Mind
- The paper speculates about causes of unconfirmed positives but does not identify a responsible prescribed drug.
Test Studied
- ARK Fentanyl II and Lin-Zhi FEN2 compared with LC-MS/MS
Source Wang et al., Forensic Sci Int 2011
What It Found
- A historical 2 ng/mL urine HEIA was evaluated against LC-MS/MS.
Source Snyder et al., Clin Chim Acta 2011
What It Found
- In a separate chronic opioid therapy cohort, Immunalysis HEIA detected 37 of 38 LC-MS/MS-positive urine specimens in the initial evaluation.
Source Chokkalla et al., EJIFCC 2025
What It Found
- The authors classified positive fentanyl screens after labor epidural fentanyl as expected in their obstetric cohort.
Keep in Mind
- The study was about confirmatory practice and did not confirm each epidural exposure separately.
Test Studied
- Perinatal urine drug screening in a laboratory stewardship study
What It Found
- The same investigators' preliminary report found only 0.05–0.20% relative response to norfentanyl in fortified urine.
2 sources Tiscione and Wegner, J Anal Toxicol 2017 Wegner and Tiscione, American Academy of Forensic Sciences Annual Scientific Meeting, abstract K14 2015
Keep in Mind
- This is evidence of weak recognition of a real metabolite on the studied reagent.
Test Studied
- Neogen fentanyl RTU ELISA, 1 and 5 ng/mL urine decision points
Source Tiscione and Wegner, J Anal Toxicol 2017
Keep in Mind
- Final-paper abstract does not give the individual percentages.
2 sources Wang et al., Forensic Sci Int 2011 Snyder et al., Clin Chim Acta 2011
Test Studied
- Historical fentanyl urine homogeneous enzyme immunoassays, including Immunalysis HEIA
Suspected, but Not Proven
Ziprasidone
Source Waters and Tewksbury, J Am Pharm Assoc (2003) 2022
What It Found
- A patient taking ziprasidone had an unexpected fentanyl screen.
- The authors suspected ziprasidone because of the history and its structural relationship to risperidone.
Keep in Mind
- The report does not establish reproducible cross-reactivity or document a definitive negative confirmation in the indexed abstract.
Test Studied
- Emergency-department urine fentanyl immunoassay, platform unspecified in abstract
Iloperidone
Source HelloPharmacist. What Drugs Cause Fentanyl False-Positives?, 2022
What It Found
- Our earlier answer on fentanyl false positives lists iloperidone.
Source Wang et al., J Anal Toxicol 2014
What It Found
- The study usually cited for it tested risperidone and its active metabolite, 9-hydroxyrisperidone, on the DRI fentanyl screen, and reported no result for iloperidone.
Both sources HelloPharmacist. What Drugs Cause Fentanyl False-Positives?, 2022 Wang et al., J Anal Toxicol 2014
Keep in Mind
- Iloperidone looks a little like risperidone in structure, but that alone does not show it affects the test.
- We found no study that tested it on a urine fentanyl screen.
Test Studied
- No iloperidone-specific clinical urine assay established in the reviewed sources
Tested: No False Positive Found
Alpha methylfentanyl
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed 5% relative response to Alpha methylfentanyl.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
Lidocaine
Source Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, FDA 510(k) decision summary K161216, 2017
What It Found
- At 100,000 ng/mL, lidocaine did not change the near-cutoff classifications in the SEFRIA urine interference experiment.
Keep in Mind
- Experiments in which concentrated material is tested directly with strips for drug checking are a different use and cannot be carried over to urine screening.
Test Studied
- SEFRIA urine fentanyl assay, FDA K161216
Lofentanil
Source Mao et al., J Pharm Biomed Anal 2006
What It Found
- The experimental antibody showed less than 1% relative response to Lofentanil.
Keep in Mind
- The abstract does not separately identify a urine matrix for the binding measurement.
- This is analytical evidence for the antibody, not a patient result.
Test Studied
- Experimental competitive anti-fentanyl ELISA evaluated for serum and urine
Remifentanil
Source Hightop Fentanyl/Norfentanyl Urine Rapid Test Panel and home-use panel, FDA 510(k)…, 2024
What It Found
- Remifentanil did not produce a positive at the tested concentration of 20,000 ng/mL on this fentanyl line.
Test Studied
- Hightop rapid urine panel, fentanyl line at 1 ng/mL
Source Wolf et al., Clin Biochem 2025
What It Found
- None of the four reagents detected added Remifentanil in the study’s series tested at 1, 10 and 100 ng/mL.
Keep in Mind
- This addresses the parent drug over the tested concentration range.
Test Studied
- ARK Fentanyl II, Immunalysis Fentanyl Urine HEIA, Immunalysis SEFRIA, and Lin-Zhi Fentanyl II
Both sources Hightop Fentanyl/Norfentanyl Urine Rapid Test Panel and home-use panel, FDA 510(k)…, 2024 Wolf et al., Clin Biochem 2025
Keep in Mind
- Other fentanyl analogues reacted differently, and other assays may give different results.
- Results need not extend to other reagents or metabolites.